14 Recruiting Carcinoma, Non-Small-Cell Lung Clinical Trials in Alabama
Explore active carcinoma, non-small-cell lung research studies enrolling across Alabama. Verify eligibility and contact site coordinators.
📍 Find Near Me by DistanceBrowse by City
Recruiting Carcinoma, Non-Small-Cell Lung Studies in Alabama
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research
MYLUNG Consortium Study Protocol 2
📍 Southern Cancer Center, PC — Daphne, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
THIO Sequenced With Cemiplimab in Advanced NSCLC
📍 Central Alabama Research — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
📍 Research Site — Tuscaloosa, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
📍 Infirmary Cancer Care ( Site 0418) — Mobile, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
📍 University of Alabama at Birmingham, Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
📍 Brookwood Medical Center — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
📍 Southern Cancer Center, PC — Mobile, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
📍 Southern Cancer Center, PC — Daphne, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
📍 Clearview Cancer Institute — Huntsville, Alabama
View Study & Checklist ➔ 🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research
MYLUNG Consortium Part 3: Observational Study
📍 Southern Cancer Center, PC — Daphne, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
📍 Clearview Cancer Institute — Huntsville, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
📍 Local Institution - 0347 — Birmingham, Alabama
View Study & Checklist ➔